OIE Reference Laboratory Reports Activities
Activities in 2018

This report has been submitted: 2019-01-25 15:16:21

<table>
<thead>
<tr>
<th>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</th>
<th>Q fever</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Address of laboratory:</strong></td>
<td>Anses (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail), Laboratoire de Sophia Antipolis, Unité de Fièvre Q animale, 105, route des Chappes, BP 111, 06902 Sophia Antipolis, FRANCE</td>
</tr>
<tr>
<td><strong>Tel.:</strong></td>
<td>+33-4 92.94.37.00</td>
</tr>
<tr>
<td><strong>Fax:</strong></td>
<td>+33-4 92.94.37.01</td>
</tr>
<tr>
<td><strong>E-mail address:</strong></td>
<td><a href="mailto:elodie.rousset@anses.fr">elodie.rousset@anses.fr</a></td>
</tr>
<tr>
<td><strong>Website:</strong></td>
<td><a href="https://www.anses.fr/fr/content/laboratoire-de-sophia-antipolis">https://www.anses.fr/fr/content/laboratoire-de-sophia-antipolis</a></td>
</tr>
<tr>
<td><strong>Name (including Title) of Head of Laboratory (Responsible Official):</strong></td>
<td>Richard Thiéry</td>
</tr>
<tr>
<td><strong>Name (including Title and Position) of OIE Reference Expert:</strong></td>
<td>Elodie Rousset</td>
</tr>
<tr>
<td><strong>Which of the following defines your laboratory? Check all that apply:</strong></td>
<td>Governmental</td>
</tr>
</tbody>
</table>
ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

<table>
<thead>
<tr>
<th>Diagnostic Test</th>
<th>Indicated in OIE Manual (Yes/No)</th>
<th>Total number of test performed last year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nationally</td>
<td>Internationally</td>
</tr>
<tr>
<td>Indirect diagnostic tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELISA sérum ruminants</td>
<td>Oui (en noir)</td>
<td>656</td>
</tr>
<tr>
<td>ELISA sérum multi-espece</td>
<td>Non (exploratoire)</td>
<td>171</td>
</tr>
<tr>
<td>Direct diagnostic tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR Temps Reel Quantitative</td>
<td>Oui (en noir)</td>
<td>953</td>
</tr>
<tr>
<td>Génotypage MLVA</td>
<td>Non</td>
<td>0</td>
</tr>
<tr>
<td>Isolement (souris, culture)</td>
<td>Oui (en noir)</td>
<td>0</td>
</tr>
<tr>
<td>WGS</td>
<td>Non</td>
<td>0</td>
</tr>
</tbody>
</table>

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes
<table>
<thead>
<tr>
<th>Type of reagent available</th>
<th>Related diagnostic test</th>
<th>Produced/provide</th>
<th>Amount supplied nationally (ml, mg)</th>
<th>Amount supplied internationally (ml, mg)</th>
<th>No. of recipient OIE Member Countries</th>
<th>Region of recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sérum étalon (0.5 mL unité)</td>
<td>Fixation du Complément</td>
<td>Produit</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Africa America Asia and Pacific Europe Middle East</td>
</tr>
<tr>
<td>Sérum calibrant (0.4 mL unité)</td>
<td>ELISA (sérologie)</td>
<td>Produit</td>
<td>54 unités (21.6 mL)</td>
<td>23 unités (9.2 mL)</td>
<td>6</td>
<td>Africa America Asia and Pacific Europe Middle East</td>
</tr>
<tr>
<td>Standard ADN génomique (0.05 mL unité)</td>
<td>PCR, Génotypage</td>
<td>Produit</td>
<td>14 unités (0.7 mL)</td>
<td>3 unités (0.15 mL)</td>
<td>2</td>
<td>Africa America Asia and Pacific Europe Middle East</td>
</tr>
<tr>
<td>Bactéries purifiées inactivées dosées (1mL unité)</td>
<td>PCR</td>
<td>Produit</td>
<td>13 unités (13 mL)</td>
<td>2 unités (2 mL)</td>
<td>2</td>
<td>Africa America Asia and Pacific Europe Middle East</td>
</tr>
</tbody>
</table>

4. Did your laboratory produce vaccines?  
No

5. Did your laboratory supply vaccines to OIE Member Countries?  
No

**ToR 3: To develop, standardise and validate, according to OIE Standards, new**
procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?
No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?
No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?
No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?
Yes

<table>
<thead>
<tr>
<th>Name of the OIE Member Country receiving a technical consultancy</th>
<th>Purpose</th>
<th>How the advice was provided</th>
</tr>
</thead>
<tbody>
<tr>
<td>DENMARK</td>
<td>Appui à la mise en place de 2 méthodes sérologiques ELISA (2 kits), demande de sérum pour évaluation, dans un contexte de nouvelles missions pour l’institut demandeur</td>
<td>Fourniture de sérum qualifié pour ces mêmes kits dans un précédent EILA. Echanges par mails : explications/conseils (situation des méthodes sérologiques fièvre Q, témoins de reproductibilité / carte de contrôle, conservation des sérum, ...), discussions sur les résultats, dont information sur une modification d’un kit courant 2017 vs impact sur les résultats. Proposition de participation à l’EILA pour les méthodes sérologiques par ELISA en 2019.</td>
</tr>
<tr>
<td>SERBIA</td>
<td>Aide pour l’organisation d’un premier EILA national pour les méthodes sérologiques par ELISA</td>
<td>Explications et conseils (par mails)</td>
</tr>
<tr>
<td>MEXICO</td>
<td>Accompagnement mise en place PCRq</td>
<td>Echanges par mails : proposition de fourniture de matériaux de référence pour PCR et explications/conseils (utilisation des MR, méthodes PCR existantes dont les kits validés, procédé de validation, cibles PCR). En cours.</td>
</tr>
</tbody>
</table>
ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

<table>
<thead>
<tr>
<th>Title of the study</th>
<th>Duration</th>
<th>Purpose of the study</th>
<th>Partners (Institutions)</th>
<th>OIE Member Countries involved other than your country</th>
</tr>
</thead>
<tbody>
<tr>
<td>DISCONTTOOL : overview on Q fever and the gaps still existing</td>
<td>1 an</td>
<td>Contribution à l’actualisation de la database discontool</td>
<td>WUR (Pays-Bas, leader) ; RIVM (Pays-Bas), GD Animal Health (Pays-bas); Bundeswehr (Allemagne) ; IZS Venezie (Italie); Coda-Cerva (Belgique), INSA (Portugal), ONIRIS (France), CNR (France), CEVA</td>
<td>GERMANY BELGIUM ITALY THE NETHERLANDS PORTUGAL</td>
</tr>
</tbody>
</table>

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 6


b) International conferences: 3


c) National conferences: 3


d) Other:
(Provide website address or link to appropriate information) 5
Chapitre :
Actualisation du chapitre sur la fièvre Q dans la database DISCONTOOL
https://discontools.eu/database/57-q-fever.html

Publications dans des revues professionnelles :

Rapports de projet, d’expertise, et documents d’appui scientifique et technique :


Rousset, E. 2018. Actualisation de la "Liste des méthodes PCR (temps réel) pour la recherche de Coxiella burnetii
ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 1
b) Seminars: 2
c) Hands-on training courses: 1
d) Internships (>1 month): 1

<table>
<thead>
<tr>
<th>Type of technical training provided (a, b, c or d)</th>
<th>Country of origin of the expert(s) provided with training</th>
<th>No. participants from the corresponding country</th>
</tr>
</thead>
<tbody>
<tr>
<td>a</td>
<td>Egypte</td>
<td>2</td>
</tr>
<tr>
<td>b</td>
<td>Egypte</td>
<td>&gt;10</td>
</tr>
<tr>
<td>b</td>
<td>Egypte</td>
<td>&gt;10</td>
</tr>
<tr>
<td>c</td>
<td>Egypte</td>
<td>&gt;10</td>
</tr>
<tr>
<td>d</td>
<td>Brésil</td>
<td>1</td>
</tr>
</tbody>
</table>

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System certified according to an International Standard?

Yes

<table>
<thead>
<tr>
<th>Quality management system adopted</th>
<th>Certificate scan (PDF, JPG, PNG format)</th>
</tr>
</thead>
</table>

16. Is your laboratory accredited by an international accreditation body?

Yes
<table>
<thead>
<tr>
<th>Test for which your laboratory is accredited</th>
<th>Accreditation body</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA sur sérum : IDEXX Q Feber Ab Test (IDEXX)</td>
<td>COFRAC</td>
</tr>
<tr>
<td>ELISA sur sérum : ID Screen® Q fever indirect (ID.vet)</td>
<td>COFRAC</td>
</tr>
<tr>
<td>ELISA sur sérum : PrioCHECK™ Ruminant Q Fever Ab Plate Kit (ThermoFischerscientific)</td>
<td>COFRAC</td>
</tr>
</tbody>
</table>

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?  
Yes  
*(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)*

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?  
No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?  
No

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?  
Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?  
No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?  
No
ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

<table>
<thead>
<tr>
<th>Purpose for inter-laboratory test comparisons</th>
<th>No. participating laboratories</th>
<th>Region(s) of participating OIE Member Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Méthodes PCR temps réel pour le diagnostic d'avortement des ruminants (méthodes validées conseillées)</td>
<td>54</td>
<td>□Africa □Americas □Asia and Pacific □Europe □Middle East</td>
</tr>
</tbody>
</table>

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

Les pays ayant participés à l'EILA PCR tenu en 2018 étaient : l’Allemagne (2 participants), l’Autriche (1), le Chili (2), le Danemark (1), l’Espagne (2), la Finlande (1), la Hongrie (1), l’Italie (2), la la Lettonie (1), les Pays-Bas (1) et la Serbie (2).